Drug intelligence / Profile preview

MDH-313

Development stage: Unknown
Lead developer: MD Healthcare
Modality: Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

MDH-313 is a microbial extracellular vesicle (EV)-based therapeutic under development by MD Healthcare for the treatment of solid cancers and childhood cancers. Derived from commensal microbes, these extracellular vesicles act as nonliving biological nanoparticles that can penetrate cellular organelles and target distant organs to modulate the immune system and induce protective anti-tumor responses. MDH-313 is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on MDH-313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDH-313.

Explore the full profile